Recently, the CRC Subtype Consortium (CRCSC), analyzing and merging different subtyping algorithms based on several gene expression data sets, identified 4 CRC consensus molecular subtypes: CMS1 (14% MSI immune: hypermutated, MSI, with a strong immune activation), CMS2 (37% canonical: epithelial, marked WNT and MYC signaling activation), CMS3 (13% metabolic: epithelial and metabolic dysregulation), and CMS4 (23% mesenchymal: TGF-β activation, stromal invasion and angiogenesis). Here, MYC is linked to colorectal carcinoma.